TG Therapeutics is a biopharmaceutical company focused on developing and delivering medicines for patients with B-cell mediated diseases. TG has five drug candidates in development, with ublituximab (TG-1101) and umbralisib (TGR-1202) in pivotal trials for CLL, NHL and MS. Ublituximab is a glycoengineered anti-CD20 monoclonal antibody and umbralisib is an oral, once-daily PI3K-delta inhibitor that uniquely inhibits CK1-epsilon. In early clinical development TG has an anti-PD-L1 monoclonal antibody (TG-1501), an oral BTK inhibitor (TG-1701), and an anti-CD47/CD19 bispecific antibody (TG-1801).